Sandbox:Aneeza: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (added the overview of the topic)
Line 1: Line 1:
<ref></ref>
__NOTOC__
===={{CMG}}; {{AE}} {{Aneeza Jamshed}}====
===={{CMG}}; {{AE}} {{Aneeza Jamshed}}====


Line 8: Line 4:


===OVERVIEW:===
===OVERVIEW:===
Libman-sack endocarditis is the on of the cardiac manifestations of  autoimmune systemic diseases most commonly [[Systemic lupus erythematosus|Systemic Lupus Erythematosus]]
Libman-sack endocarditis is the one of the cardiac manifestations of  autoimmune systemic diseases most commonly [[Systemic lupus erythematosus|Systemic Lupus Erythematosus]]. It may also be a finding in malignancy with the non-bacterial non-thrombotic involvement of the valves, most commonly the aortic and mitral valve. The most common complications include embolic phenomenon like cerebrovascular disease. The disease activity and titer of the antibodies in Systemic Lupus Erythematosus can be linked to Libman-sack Endocarditis<ref name="pmidPMID: 20422938">{{cite journal| author=Carrillo-Esper R, Carrillo-Córdova JR, Carrillo-Córdova LD, Carrillo-Córdova CA| title=[Libman-Sacks endocarditis]. | journal=Gac Med Mex | year= 2010 | volume= 146 | issue= 1 | pages= 67-9 | pmid=PMID: 20422938 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20422938  }} </ref>.
<references group="Mee J, Dong H (2007). &quot; Epidemiology of Libman-sack endocarditis&quot;. " />
.


=<nowiki>=</nowiki>=  
=<nowiki>=</nowiki>=  

Revision as of 11:34, 4 April 2021

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aneeza Jamshed, M.B.B.S.[2]

LIBMAN-SACK ENDOCARDITIS:

OVERVIEW:

Libman-sack endocarditis is the one of the cardiac manifestations of autoimmune systemic diseases most commonly Systemic Lupus Erythematosus. It may also be a finding in malignancy with the non-bacterial non-thrombotic involvement of the valves, most commonly the aortic and mitral valve. The most common complications include embolic phenomenon like cerebrovascular disease. The disease activity and titer of the antibodies in Systemic Lupus Erythematosus can be linked to Libman-sack Endocarditis[1].

=

[2] ===

High-power field of peripheral blood smear revealing a large, atypical B cell with mild cytoplasmic expansion, coarse chromatin, multiple distinct nucleoli and peripheral vacuolation.Source: Charakidis M. et al, Department of Haematology-Oncology, Royal Hobart Hospital, Tasmania, 7000, Australia.


Classification of Waldenstrom macroglobulinemia (WM) and Related Disorders
Criteria Symptomatic WM Asymptomatic WM IgM-Related Disorders MGUS
IgM monoclonal protein + + + +
Bone marrow infiltration + + - -
Symptoms attributable to IgM + - + -
Symptoms attributable to tumor infiltration + - - -


Libman-Sacks endocarditis Microchapters

Overview

Historical Perspective

Pathophysiology

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Imaging Findings

Other Diagnostic Studies

Treatment

Differentiating Libman-Sacks Endocarditis from other Diseases



Reference

  1. Carrillo-Esper R, Carrillo-Córdova JR, Carrillo-Córdova LD, Carrillo-Córdova CA (2010). "[Libman-Sacks endocarditis]". Gac Med Mex. 146 (1): 67–9. PMID 20422938 PMID: 20422938 Check |pmid= value (help).
  2. Mao Y, Yang D, He J, Krasna MJ (2016). "Epidemiology of Lung Cancer". Surg Oncol Clin N Am. 25 (3): 439–45. doi:10.1016/j.soc.2016.02.001. PMID 27261907.